Evaluation of Tissue PCA3 Expression in Prostate Cancer by RNA in Situ Hybridization--a Correlative Study with Urine PCA3 and TMPRSS2-ERG

Overview

Journal Mod Pathol

Specialty Pathology

Date 2013 Sep 28

PMID 24072184

Citations 14

Authors

Joshua I Warrick

Scott A Tomlins

Shannon L Carskadon

Allison M Young

Javed Siddiqui

John T Wei

Arul M Chinnaiyan

Lakshmi P Kunju

Nallasivam Palanisamy

Affiliations

Soon will be listed here.

Abstract

PCA3 is a prostate-specific non-coding RNA, with utility as a urine-based early detection biomarker. Here, we report the evaluation of tissue PCA3 expression by RNA in situ hybridization in a cohort of 41 mapped prostatectomy specimens. We compared tissue PCA3 expression with tissue level ERG expression and matched pre-prostatectomy urine PCA3 and TMPRSS2-ERG levels. Across 136 slides containing 138 foci of prostate cancer, PCA3 was expressed in 55% of cancer foci and 71% of high-grade prostatic intraepithelial neoplasia foci. Overall, the specificity of tissue PCA3 was >90% for prostate cancer and high-grade prostatic intraepithelial neoplasia combined. Tissue PCA3 cancer expression was not significantly associated with urine PCA3 expression. PCA3 and ERG positivity in cancer foci was positively associated (P<0.01). We report the first comprehensive assessment of PCA3 expression in prostatectomy specimens, and find limited correlation between tissue PCA3 and matched urine in prostate cancer.

Citing Articles

Endocrine nuclear receptors and long non‑coding RNAs reciprocal regulation in cancer (Review).

Cantile M, Cerrone M, di Bonito M, Moccia P, Tracey M, Ferrara G Int J Oncol. 2023; 64(1).

PMID: 38038050 PMC: 10705039. DOI: 10.3892/ijo.2023.5595.

LncRNA LASTR promote lung cancer progression through the miR-137/TGFA/PI3K/AKT axis through integration analysis.

Xia M, Zhu W, Tao C, Lu Y, Gao F J Cancer. 2022; 13(4):1086-1096.

PMID: 35281858 PMC: 8899365. DOI: 10.7150/jca.66067.

Exosomes as A Next-Generation Diagnostic and Therapeutic Tool in Prostate Cancer.

Gaglani S, Gonzalez-Kozlova E, Lundon D, Tewari A, Dogra N, Kyprianou N Int J Mol Sci. 2021; 22(18).

PMID: 34576294 PMC: 8465219. DOI: 10.3390/ijms221810131.

Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression.

Goel S, Bhatia V, Kundu S, Biswas T, Carskadon S, Gupta N Nat Commun. 2021; 12(1):5325.

PMID: 34493733 PMC: 8423767. DOI: 10.1038/s41467-021-25623-2.

Pseudogene Associated Recurrent Gene Fusion in Prostate Cancer.

Chakravarthi B, Dedigama-Arachchige P, Carskadon S, Sundaram S, Li J, Wu K Neoplasia. 2019; 21(10):989-1002.

PMID: 31446281 PMC: 6713813. DOI: 10.1016/j.neo.2019.07.010.

References

Auprich M, Bjartell A, Chun F, De La Taille A, Freedland S, Haese A . Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol. 2011; 60(5):1045-54. DOI: 10.1016/j.eururo.2011.08.003. View

Young A, Palanisamy N, Siddiqui J, Wood D, Wei J, Chinnaiyan A . Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden. Am J Clin Pathol. 2012; 138(5):685-96. PMC: 3597433. DOI: 10.1309/AJCPU7PPWUPYG8OH. View

Tomlins S, Aubin S, Siddiqui J, Lonigro R, Sefton-Miller L, Miick S . Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med. 2011; 3(94):94ra72. PMC: 3245713. DOI: 10.1126/scitranslmed.3001970. View

Tomlins S, Bjartell A, Chinnaiyan A, Jenster G, Nam R, Rubin M . ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol. 2009; 56(2):275-86. DOI: 10.1016/j.eururo.2009.04.036. View

Stephan C, Jung K, Semjonow A, Schulze-Forster K, Cammann H, Hu X . Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin Chem. 2012; 59(1):280-8. DOI: 10.1373/clinchem.2012.195560. View

Tomlins S, Palanisamy N, Siddiqui J, Chinnaiyan A, Kunju L . Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. Arch Pathol Lab Med. 2012; 136(8):935-46. PMC: 3667408. DOI: 10.5858/arpa.2011-0424-OA. View

Lin D, Newcomb L, Brown E, Brooks J, Carroll P, Feng Z . Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res. 2013; 19(9):2442-50. PMC: 3674574. DOI: 10.1158/1078-0432.CCR-12-3283. View

Tomlins S, Laxman B, Dhanasekaran S, Helgeson B, Cao X, Morris D . Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature. 2007; 448(7153):595-9. DOI: 10.1038/nature06024. View

Rubin M, Maher C, Chinnaiyan A . Common gene rearrangements in prostate cancer. J Clin Oncol. 2011; 29(27):3659-68. PMC: 4874145. DOI: 10.1200/JCO.2011.35.1916. View

10.

Bussemakers M, van Bokhoven A, Verhaegh G, Smit F, Karthaus H, Schalken J . DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999; 59(23):5975-9. View

11.

Vukovic B, Park P, Al-Maghrabi J, Beheshti B, Sweet J, Evans A . Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma. Oncogene. 2003; 22(13):1978-87. DOI: 10.1038/sj.onc.1206227. View

12.

Qian J, Bostwick D, Takahashi S, Borell T, Herath J, Lieber M . Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res. 1995; 55(22):5408-14. View

13.

Cornu J, Cancel-Tassin G, Egrot C, Gaffory C, Haab F, Cussenot O . Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer. Prostate. 2012; 73(3):242-9. DOI: 10.1002/pros.22563. View

14.

Park K, Tomlins S, Mudaliar K, Chiu Y, Esgueva R, Mehra R . Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010; 12(7):590-8. PMC: 2907585. DOI: 10.1593/neo.10726. View

15.

Falzarano S, Zhou M, Carver P, Tsuzuki T, Simmerman K, He H . ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch. 2011; 459(4):441-7. DOI: 10.1007/s00428-011-1128-4. View

16.

Kumar-Sinha C, Tomlins S, Chinnaiyan A . Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008; 8(7):497-511. PMC: 2711688. DOI: 10.1038/nrc2402. View

17.

Mosquera J, Perner S, Genega E, Sanda M, Hofer M, Mertz K . Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res. 2008; 14(11):3380-5. PMC: 3717517. DOI: 10.1158/1078-0432.CCR-07-5194. View

18.

Schmidt U, Fuessel S, Koch R, Baretton G, Lohse A, Tomasetti S . Quantitative multi-gene expression profiling of primary prostate cancer. Prostate. 2006; 66(14):1521-34. DOI: 10.1002/pros.20490. View

19.

Braun M, Goltz D, Adler D, Vogel W, Bohm D, Scheble V . ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies. Prostate Cancer Prostatic Dis. 2012; 15(2):165-9. DOI: 10.1038/pcan.2011.67. View

20.

Marks L, Fradet Y, Deras I, Blase A, Mathis J, Aubin S . PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 2007; 69(3):532-5. DOI: 10.1016/j.urology.2006.12.014. View